would be 40. Compared with the number needed to treat of 41 from the ATTC, 3 continued use of aspirin, even with gastroprotection, might be hurting more people than it helps. Furthermore, the harms of long-term PPI use, including malabsorption, Clostridium difficile infection, and fracture, must be considered.
No dedicated trials have shown the benefit of antiplatelet therapy in elderly people. 4 The ASPREE trial 5 seeks to find data on primary prevention of cardiovascular disease, as well as dementia and malignancy, in people older than 70 years. No trials of secondary prevention of cardiovascular disease in the elderly are planned. In a world of prescription cascades and polypharmacy, we should always think to subtract before we add.
I declare no competing interests. cancer in people who are middleaged, 1,2 but should then be gradually withdrawn because of the high risk of bleeding at older ages. We await the results of the ASPREE trial, 3 which should provide definitive evidence of the short-term benefits and harms of aspirin use in people older than 70 years.
Cody Magnusson
In terms of secondary prevention after transient ischaemic attack or stroke, there is good evidence that aspirin reduces the risk of early recurrent events irrespective of age. 4 Sudden discontinuation of antiplatelet treatment is hazardous, but in view of the high risk and poor outcome of bleeds in older patients in our study, we stated that "a trial of gradual withdrawal would be justifiable". Indeed, we also highlighted the need for a withdrawal trial in our previous report of the time course of effect of aspirin in secondary prevention of vascular events, 4 but showed that patients aged 75 years or older do gain substantial benefit from aspirin in the first few months after a transient ischaemic attack or ischaemic stroke (table). A trial of gradual withdrawal of aspirin, perhaps starting 1 year after after a transient ischaemic attack or stroke, in patients aged 75 years or older or at a later stage when patients on longer-term treatment reach 
